AbbVie
1 North Waukegan Road
North Chicago
Illinois
60064
United States
Tel: 1-800-255-5162
Website: http://www.abbvie.com/
Email: customerservice@abbvie.com
About AbbVie
AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, and YouTube.
Stock Symbol: ABBV
Stock Exchange: NYSE
We’re a company that takes on the toughest health challenges. But we do more than treat diseases—we aim to make a remarkable impact on people’s lives. We are AbbVie, a highly focused research-driven biopharmaceutical company.
1559 articles with AbbVie
-
Experience the JUVÉDERM® Difference with Allergan Aesthetics
8/17/2022
Allergan Aesthetics, an AbbVie company, invites consumers to experience the JUVÉDERM® difference.
-
I-Mab quietly announced that its partner AbbVie is ending a Phase IB trial on lemzoparlimab for two types of cancers, despite a $2 billion deal inked in 2020.
-
Genmab Announces Financial Results for the First Half of 2022
8/10/2022
Genmab Announces Financial Results for the First Half of 2022.
-
Job descriptions are the candidate's first impression of a company. And if that introduction includes exclusionary language, they're less likely to apply even if they are the perfect fit for the job.
-
A recent report predicts multiple acquisitions are set to be announced in the second half of the year, particularly by companies that have strong revenue streams from COVID-19 products.
-
AbbVie and Sosei add neurological targets in new deal, TransCode and MD Anderson partner on RNA cancer therapies and Xenetic and VolitionRx unite to develop NETs-targeted therapies against cancer.
-
Sosei Heptares and AbbVie Enter New Multi-target Collaboration to Discover, Develop and Commercialize Novel Medicines Targeting Neurological Diseases
8/1/2022
Sosei Group Corporation (“the Company”; TSE: 4565) and AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announce they have entered a new drug discovery collaboration and option-to-license agreement to discover, develop and commercialize small molecules that modulate novel G protein-coupled receptor (GPCR) targets associated with neurological disease.
-
AbbVie Reports Second-Quarter 2022 Financial Results
7/29/2022
AbbVie (NYSE:ABBV) announced financial results for the second quarter ended June 30, 2022.
-
RINVOQ® (upadacitinib) Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis
7/29/2022
AbbVie announced that the European Commission has approved RINVOQ®, an oral therapy, for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation, as indicated by elevated C-reactive protein and/or magnetic resonance imaging, who have responded inadequately to nonsteroidal anti-inflammatory drugs.
-
AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Crohn's Disease
7/27/2022
AbbVie (NYSE: ABBV) today announced that it has submitted applications for a new indication to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for upadacitinib (RINVOQ®, 45 mg [induction dose] and 15 mg and 30 mg [maintenance dose]) for the treatment of adult patients with moderately to severely active Crohn's disease.4,11
-
European Commission Approves RINVOQ® (upadacitinib) for the Treatment of Adults With Moderate to Severe Ulcerative Colitis
7/26/2022
AbbVie (NYSE: ABBV) today announced the European Commission (EC) approved RINVOQ® (upadacitinib 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.
-
AbbVie and Allergan Aesthetics to Present New Data from Leading Neurotoxin Portfolio at TOXINS 2022 Conference
7/25/2022
AbbVie (NYSE: ABBV) and Allergan Aesthetics announced today that more than 30 abstracts, including seven podium presentations, will be presented during the upcoming TOXINS 2022 Conference, July 27-30 in New Orleans.
-
Sandoz hopes its high-concentration formulation of an already greenlit biosimilar will be approved by the time AbbVie’s blockbuster drug Humira loses patent protection in the United States.
-
AbbVie and iSTAR Medical Announce Strategic Alliance for the Treatment of Glaucoma
7/20/2022
AbbVie (NYSE: ABBV) and iSTAR Medical SA, today announced a strategic transaction to further develop and commercialize iSTAR Medical's MINIject® device, a minimally invasive glaucoma surgical (MIGS) device for patients with glaucoma.
-
AbbVie Submits Marketing Authorization Application to EMA for Atogepant for the Preventive Treatment of Migraine
7/18/2022
AbbVie announced it has submitted a marketing authorization application to the European Medicines Agency for atogepant for the prophylaxis of migraine in adult patients who have at least four migraine days per month.
-
Genmab Announces That AbbVie Will Submit Marketing Authorization Application to European Medicines Agency for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
7/18/2022
Genmab A/S announced that AbbVie will submit a conditional marketing authorization application with the European Medicines Agency for subcutaneous epcoritamab, an investigational bispecific antibody, for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma, in the second half of 2022.
-
Gossamer Bio sold shares of its common stock to pave its runway through mid-2024 while Teva and AbbVie reach deals in opioid settlements.
-
AbbVie to Host Second-Quarter 2022 Earnings Conference Call
7/8/2022
AbbVie (NYSE: ABBV) will announce its second-quarter 2022 financial results on Friday, July 29, 2022, before the market opens.
-
In a filing with the SEC, Abbvie's decision to terminate came after the two firms jointly conducted a review of their next steps for the drug.
-
A Senate Finance Committee report shows the majority of AbbVie's income is taxed through foreign subsidiaries, allowing the company to pay less than half the U.S. corporate tax rate.